

2018 Oral ondansetron (oral generic Zofran®) Prior Authorization Request oral ondansetron is available in tablets, oral disintegrating tablets (ODT) and oral solution

Page 1 of 2

(You must complete both pages.)

Fax completed form to: 1-800-639-9158 For urgent requests, please call: 1-800-551-2694

Patient information		Prescriber information			
Patient name		Today's date	Physician specialty		
Patient insurance ID number		Physician name		NPI/DEA number	
Patient address, city, state, ZIP		Physician address, city, state, ZIP			
Patient home telephone number		MD office telephone number			
Gender Male Female	Patient date of birth	MD office fax number	ID office fax number		
Diagnosis and medical informati	on				
Medication requested			Frequency		
ondansetron hcl: 8 mg table					
ondansetron orally disintegrating tablets (ODT): 8 mg tablet 4 mg tablet					
New prescription OR date therap	y initiated	Quantity	Day supply	Expected length of therapy	
Diagnosis (Blasse shock all baye	as that apply and include all office	notes supporting disapp	oie)	<u>.</u>	
Diagnosis (Please check all boxes that apply and include all office notes supporting diagnosis.)					
☐ Chemotherapy-induced nausea and vomiting, highly emetogenic chemotherapy, prophylaxis ☐ Chemotherapy-induced nausea and vomiting, moderately emetogenic chemotherapy, prophylaxis					
Postoperative nausea and vomiting, prophylaxis					
Radiation-induced nausea and vomiting, prophylaxis					
Other diagnosis/(ICD 10):					
Please check all boxes that apply:					
1. Yes No Is oral ondansetron being used for chemotherapy induced nausea and vomiting? If YES, complete the section below.					
a. Cancer diagnosis:					
	n:				
c. Frequency of cancer chemotherapy:					
d. Cancer chemotherapy route of administration:					
e. Where is the chemotherapy being administered? Home Outpatient infusion center Other:					
☐ Yes ☐ No Is the requested drug being used as a full therapeutic replacement* for an intravenous antiemetic (IV) drug that would otherwise have been administered at the time of the chemotherapy treatment? *Full therapeutic replacement for an IV antiemetic is when the patient DID NOT receive any doses of IV antiemetic at the time of chemotherapy administration.					
☐ Yes ☐ No Will the requested drug be given within two hours of chemotherapy administration AND continued for a period NOT EXCEEDING 48 hours from that time?					
☐ Yes ☐ No Will the request	of chemotherapy administrat	ion for ongoing	g nausea/vomiting?		

(continued on page 2)

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-551-2694.



Page 2 of 2

Please check all boxes that apply (continued):						
2. Yes No The quantity limit for ondansetron oral solution 4mg/5ml is 900 ml per 30 days. Does the patient require higher dosage (quantity limit exception)?						
►If YES , indicate quantity red	quested: per 30 days	OR quantity	_ per day			
The number of doses available under the dose restriction for the prescription drug has been ineffective in the treatment of the enrollee's disease or medical condition.						
The number of doses available under the dose restriction for the prescription drug, based on both sound clinical evidence and medical and scientific evidence, the known relevant physical or mental characteristics of the enrollee and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug's effectiveness or patient compliance.						
3. ☐ Please list all medications the patient has tried specific to the diagnosis and specify below.						
CURRENT/PAST MEDICATIONS USED	DATES OF TREATMENT	THERAPEUTIC OUTCOM	IE			
4. Other supporting information						
*NOTE: All exception requests require prescriber supporting statements. Additionally, requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request.						
			_			
-			_			
I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true,						
and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is						
material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble						
damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and						
Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.						
Prescriber signature		Date				

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-551-2694.